Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Pfizer’s Comirnaty Up for PAFSC Review for Ages 5-11 on Jan. 20; Actemra to Add COVID-19 Use
January 14, 2022
-
BUSINESS Keytruda, Opdivo Neck and Neck in 2021; 6 Drugs Cross 100 Billion Yen Mark: Encise
January 13, 2022
-
REGULATORY AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
-
REGULATORY MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official
January 11, 2022
-
REGULATORY Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
-
REGULATORY MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
-
ORGANIZATION FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
-
BUSINESS Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
-
BUSINESS Nexium and Feburic Generic Debuts Eyed in 2022, but with Caution to Avoid Shortages
January 5, 2022
-
REGULATORY Japan Govt to End Observational Avigan Study for COVID-19
January 5, 2022
-
BUSINESS 5 Atopic Dermatitis Drugs Debut in Japan since 2018; Focus Now on Roles of Dupixent, JAK Inhibitors
December 28, 2021
-
TRENDS 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
-
TRENDS Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
-
REGULATORY Japan Approves Lenvima/Keytruda Pair, Opdivo Label Expansion
December 27, 2021
-
REGULATORY Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
-
REGULATORY Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
-
REGULATORY Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
-
REGULATORY Gist of FY2022 Drug Pricing Reform
December 22, 2021
-
REGULATORY Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
-
COMMENTARY Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…